1Ph.D. Scholar, Department of Rasshastra and Bhaishajya Kalpana, Mahatma Gandhi Ayurved College, Hospital and Research Centre, Salod, Wardha, Maharashtra-442001, Email: ngc609@gmail.com
2Professor, Department of Rasshastra and Bhaishajya Kalpana, Mahatma Gandhi Ayurved College Hospital and Research Centre, Salod, Wardha, Maharashtra-442001, Email: anitawanjari7@gmail.com
Tuberculosis remains a major global health challenge, particularly with the emergence of drug-resistant strains. The classical Ayurvedic formulation Nirgundi Ghrita, traditionally indicated for Rajayakshma (correlating with pulmonary tuberculosis), represents a promising adjunct therapy. This research aims to conduct comprehensive pharmaceutico-analytical evaluation and experimental validation of Nirgundi Ghrita, focusing on its antioxidant and antimycobacterial activities. The formulation will be prepared using Vitex negundo (Nirgundi) and cow ghee following classical guidelines from Chakradatta. Standardization will employ organoleptic, physicochemical, and chromatographic analyses. Antioxidant activity will be assessed through DPPH, ABTS, and FRAP assays, while antimycobacterial efficacy will be evaluated against Mycobacterium tuberculosis using the BacT/ALERT 3D automated system. Given the established role of oxidative stress in tuberculosis pathogenesis and the documented hepatoprotective, immunomodulatory, and antimicrobial properties of Vitex negundo, this study seeks to bridge traditional wisdom with evidence-based medicine. The findings will contribute to integrative tuberculosis management by validating a classical formulation that may enhance treatment outcomes, reduce drug toxicity, and strengthen host immunity through its antioxidant and antimycobacterial properties.
Keywords: Nirgundi Ghrita; Vitex negundo; Tuberculosis; Rajayakshma; Antioxidant activity; Antimycobacterial activity
How to cite this article: Wadibhasme RG, Wanjari A. A Pharmaceutico-Analytical Standardization and In-Vitro Anti-Mycobacterial Evaluation of Nirgundi Ghrita for Tuberculosis Management. Int J Drug Deliv Technol. 2026;16(1): 738-746; DOI: 10.25258/ijddt.16.1.78
Source of support: Nil.
Conflict of interest: None